Ceres Nanosciences leverages its groundbreaking Nanotrap® Particle technology to create innovative diagnostic solutions that improve patient outcomes through early disease detection. The company has developed its platform with significant backing from entities like the NIH, DARPA, the Bill & Melinda Gates Foundation, and Schmidt Futures. As a privately held firm, Ceres is positioned to expand its product portfolio across infectious disease, biodefense, and chronic illness diagnostics, collaborating with partners to integrate its technology into critical workflows.
Infectious DiseasesBiodefenseChronic Diseases
Technology Platform
Proprietary Nanotrap® Particle technology that captures, concentrates, and preserves low-abundance analytes (proteins, pathogens, nucleic acids) from biological samples to enable highly sensitive detection for diagnostics and research.
Funding History
3
Total raised:$14.6M
Series A$12MUndisclosed
Seed$2.1MUndisclosed
Grant$500KNIH
Opportunities
Significant growth opportunities exist in developing and commercializing FDA-cleared diagnostic tests for high-burden diseases like Lyme disease, where current diagnostics are inadequate.
The platform's applicability for pandemic preparedness and monitoring of chronic diseases (e.g., cancer, neurodegenerative) through non-invasive samples presents a large addressable market.
Expansion through licensing and co-development deals with global diagnostic companies offers a capital-efficient path to scale.
Risk Factors
Key risks include the technical and regulatory challenges of transitioning a platform technology into approved clinical diagnostics, dependence on strategic partnerships for commercialization, and intense competition from larger, established diagnostic companies that could develop similar capabilities.
Competitive Landscape
Ceres competes with large diagnostic reagent firms (Thermo Fisher, Roche) and specialized sample prep companies. Its differentiation lies in the unique combination of capture, concentration, and preservation offered by the Nanotrap® particles, validated by prestigious funding agencies. Success hinges on proving superior clinical sensitivity and forging partnerships to integrate into mainstream diagnostic workflows.
